Reappointment of Mr. Muthukrishnan Ramesh (DIN: 01016291) as Whole-time Director for a period of five years
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech's board, at its meeting on 30 August 2025, approved the 33rd AGM to be held on 29 September 2025 via video conferencing. The headline item is the reappointment of Mr. Muthukrishnan Ramesh (DIN: 01016291) as Whole-time Director for five years, alongside similar five-year appointments of Mr. Swaminathan and Mr. Singarababu Indirakumar as Whole-time Directors and Mrs. Bokara Nagarajan Padmaja Priyadarshini as Independent Director. The board also approved a significant divestment from its material subsidiary, Dindigul Farm Product Limited (DFPL), which contributed Rs. 6,282.81 lakhs (~47.11%) of consolidated turnover and Rs. 3,521.13 lakhs (~35.24%) of consolidated net worth in FY25, with reclassification of DFPL's promoter status to public. Additionally, authorised share capital was proposed to be raised to Rs. 85 crores (8.5 crore equity shares of Rs. 10 each), new internal and secretarial auditors were appointed, and material related party transactions up to Rs. 25 crores each were approved with multiple subsidiaries (DFPL, Matrix Boilers, HSL Agri Solutions, HSLPrime Properties, IBL Investments, and IBL Healthcare), all subject to shareholder approval.
The divestment of DFPL, which accounts for nearly half of consolidated revenue, is a major restructuring move that could materially reshape the company's revenue mix and reduce consolidated scale. The hike in authorised share capital signals room for future fundraising, while the multiple related party transactions with subsidiaries indicate significant intra-group activity that shareholders should monitor.